DCWT (03768) proposed appointing Ma Shuo as an executive director.
The Dianchi Water Corporation (03768) announced that Mr. Chen Changyong, Executive Director and General Manager, has submitted his resignation to the board of directors on May 27, 2026 due to personal work changes. He has resigned from the positions of Executive Director, member of the Strategic and Investment Decision Committee, General Manager, and authorized representative of the company as required by Rule 3.05 of the Listing Rules of the Hong Kong Stock Exchange. His resignation is effective as of the date of submission to the board of directors (i.e. May 27, 2026).
DCWT (03768) announced that Mr. Chen Chang Yong, an executive director and general manager, has submitted his resignation to the board of directors on May 27, 2026, due to personal work changes. He resigned from his positions as executive director, member of the strategic and investment decision-making committee, general manager, and authorized representative of the company as stipulated by Rule 3.05 of the Listing Rules of the Hong Kong Stock Exchange. His resignation became effective on the same day he submitted his resignation letter to the board of directors. After Mr. Chen Chang Yong's resignation became effective on May 27, 2026, the strategic and investment decision-making committee only has two members.
Mr. Xu Jingdong, a non-executive director, also submitted his resignation to the board of directors on May 27, 2026, due to personal work changes. He resigned from his position as a non-executive director, effective on the same day he submitted his resignation letter to the board of directors.
On May 27, 2026, the board of directors recommended the appointment of Mr. Ma Shuo as the executive director of the first board of directors of the company, and the appointment of Ms. Ding Heng as a non-executive director of the first board of directors of the company.
In addition, Mr. Mu Yong has been appointed as the authorized representative, effective from May 27, 2026.
Related Articles

Pharmaron Beijing (03759) plans to build a project in Shaoxing that would produce 200 tons of pharmaceutical intermediates and APIs annually.

CONSUN PHARMA (01681) plans to carry out a share buyback program.

Pharmaron Beijing (03759) plans to invest approximately 2 billion yuan to establish a new drug commercial production and CDMO research and development production service base in Qiantang District, Hangzhou City.
Pharmaron Beijing (03759) plans to build a project in Shaoxing that would produce 200 tons of pharmaceutical intermediates and APIs annually.

CONSUN PHARMA (01681) plans to carry out a share buyback program.

Pharmaron Beijing (03759) plans to invest approximately 2 billion yuan to establish a new drug commercial production and CDMO research and development production service base in Qiantang District, Hangzhou City.






